EUVIMEDObjevte EUVIMED
Crossref

Stratifying Post‐Transplant Diabetes: Prognostic Impact of Insulin Dependence and Treatment Duration

Beatriz Rodríguez-Cubillo iD, Alejandro Morales, Rómulo Katsu iD, Yunaika Díaz Enamorado, M Ángeles Moreno de la Higuera iD, Natividad Calvo Romero iD, María Muñiz iD, Arianne S Aiffil iD, Cristina Riaza iD, Pilar Matía iD, Isabel Pérez-Flores iD, Raquel Jiménez Ortego and 2 more

Clinical Transplantation · 2025

DOI: 10.1111/ctr.70374 ↗

At a glance

Journal article in Clinical Transplantation, 2025. Written by Beatriz Rodríguez-Cubillo and 13 co-authors. Institution: Department of Nephrology, Hospital Clínico San Carlos, Madrid, Spain. Major MEDLINE topics: Kidney Transplantation, Insulin, Postoperative Complications, Diabetes Mellitus. 26 references.

AbstraktSubjectsBibliografické údajeCiteRelated studies

Abstract (original language)

Background

Post‐transplant diabetes mellitus (PTDM) is a common metabolic complication after kidney transplantation. However, its long‐term prognostic impact may vary depending on the persistence and intensity of treatment. This study aimed to evaluate whether insulin‐dependent PTDM persisting beyond 12 months is associated with adverse outcomes and whether stratifying PTDM phenotypes is clinically meaningful.

Methods

We conducted a retrospective cohort study of adult kidney transplant recipients (2010–2021) with systematic follow‐up through 2023. PTDM was classified into four phenotypes: Early post‐transplant hyperglycemia (PTH), transient (12 months). Primary outcomes were patient and death‐censored graft survival; secondary outcomes included cardiovascular events and diabetes‐related complications. Multivariable logistic regression was used to identify independent predictors of mortality.

Results

A total of 346 kidney transplant recipients were included, with a median follow‐up of 8.9 years. Persistent insulin‐treated PTDM was present in 33.8% of patients and was independently associated with increased mortality [odds ratio (OR) = 2.12; 95% confidence interval (95% CI): 1.02–4.40; p = 0.043], and age. Patient survival at 10 years was significantly lower in this group (74.0%) compared to Early PTH (85.5%, p = 0.021), while graft survival remained similar across groups. No significant associations were found between PTDM phenotypes and retinopathy, cerebrovascular events, or diabetic nephropathy. Definitive steroid withdrawal was associated with reduced mortality (OR = 0.37; p = 0.012). Although SGLT2 inhibitor use did not reach statistical significance in adjusted models, none of the treated patients died during follow‐up, compared to 19.8% mortality in non‐users ( p = 0.013, in univariate analysis).

Conclusion

Persistent insulin‐treated PTDM is independently associated with poorer survival. Stratifying PTDM by phenotype helps identify high‐risk patients who may benefit from closer follow‐up and cardiometabolic optimization.

Subjects

MeSH terms (MEDLINE)

Kidney TransplantationInsulinPostoperative ComplicationsDiabetes MellitusHypoglycemic AgentsGraft RejectionHumansFemaleMaleRetrospective StudiesMiddle AgedPrognosisFollow-Up StudiesGraft SurvivalRisk FactorsSurvival RateAdultGlomerular Filtration Rate

Author keywords

cardiovascular diseasesdiabetes mellitusgraft survivalkidney transplantationmortality

Substances

InsulinHypoglycemic Agents

Authors and institutions

  • Department of Nephrology, Hospital Clínico San Carlos, Madrid, Spain.
  • Foundation For Biomedical Research of the Hospital Clínico San Carlos (IdISSC), Madrid, Spain.
  • Department of Endocrinology and Nutrition, Hospital Clínico San Carlos, Madrid, Spain.

ORCID profiles: Beatriz Rodríguez-Cubillo, Rómulo Katsu, M Ángeles Moreno de la Higuera, Natividad Calvo Romero, María Muñiz, Arianne S Aiffil, Cristina Riaza, Pilar Matía, Isabel Pérez-Flores, Ana I Sánchez-Fructuoso

Cite

APA

Rodríguez-Cubillo, B., Morales, A., Katsu, R., Enamorado, Y. D., Moreno de la Higuera, M. Á., Romero, N. C., Muñiz, M., Aiffil, A. S., Riaza, C., Matía, P., Pérez-Flores, I., Ortego, R. J., Pujol Pujol, M., & Sánchez-Fructuoso, A. I. (2025). Stratifying Post‐Transplant Diabetes: Prognostic Impact of Insulin Dependence and Treatment Duration. Clinical Transplantation. https://doi.org/10.1111/ctr.70374

Vancouver

Rodríguez-Cubillo B, Morales A, Katsu R, Enamorado YD, Moreno de la Higuera MÁ, Romero NC, et al. Stratifying Post‐Transplant Diabetes: Prognostic Impact of Insulin Dependence and Treatment Duration. Clinical Transplantation. 2025. doi:10.1111/ctr.70374

BibTeX
@article{RodrguezCubillo2025,
  author = {Rodríguez-Cubillo, Beatriz and Morales, Alejandro and Katsu, Rómulo and Enamorado, Yunaika Díaz and Moreno de la Higuera, M Ángeles and Romero, Natividad Calvo and Muñiz, María and Aiffil, Arianne S and Riaza, Cristina and Matía, Pilar and Pérez-Flores, Isabel and Ortego, Raquel Jiménez and Pujol Pujol, Marina and Sánchez-Fructuoso, Ana I},
  title = {Stratifying Post‐Transplant Diabetes: Prognostic Impact of Insulin Dependence and Treatment Duration},
  journal = {Clinical Transplantation},
  year = {2025},
  doi = {10.1111/ctr.70374}
}
Start for free →